Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (IS) (2021 - 2025)

InMed Pharmaceuticals' Depreciation & Amortization (IS) history spans 5 years, with the latest figure at $53201.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) changed 0.0% year-over-year to $53201.0; the TTM value through Dec 2025 reached $211461.0, down 2.69%, while the annual FY2025 figure was $212839.0, 3.08% down from the prior year.
  • Depreciation & Amortization (IS) reached $53201.0 in Q4 2025 per INM's latest filing, roughly flat from $53202.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $55234.0 in Q4 2023 to a low of $28532.0 in Q3 2021.
  • Average Depreciation & Amortization (IS) over 5 years is $51486.0, with a median of $53202.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (IS): surged 71.91% in 2022, then dropped 4.97% in 2023.
  • A 5-year view of Depreciation & Amortization (IS) shows it stood at $49797.0 in 2021, then dropped by 1.5% to $49049.0 in 2022, then rose by 12.61% to $55234.0 in 2023, then dropped by 3.68% to $53202.0 in 2024, then decreased by 0.0% to $53201.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Depreciation & Amortization (IS) are $53201.0 (Q4 2025), $53202.0 (Q3 2025), and $52752.0 (Q2 2025).